IMEIK(SZ:300896) EBSCN·2026-01-09 05:35Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has successfully obtained approval for its injectable type A botulinum toxin product, which is expected to drive revenue growth due to its established distribution channels and brand strength [5] - The domestic market for botulinum toxin is anticipated to have significant growth potential, as the demand is currently lower than that for hyaluronic acid, with projections indicating a compound annual growth rate (CAGR) of 27.6% from 2026 to 2030 [6] - The approval process for botulinum toxin products is stringent, which is expected to maintain a favorable competitive landscape for the company [7] - The company is projected to achieve net profits of 1.39 billion, 1.53 billion, and 1.70 billion yuan for the years 2025 to 2027, respectively, with corresponding earnings per share (EPS) of 4.58, 5.06, and 5.63 yuan [7] Financial Performance - The company’s revenue is forecasted to reach 2.43 billion yuan in 2025, with a significant decline of 19.81% compared to the previous year, followed by a recovery in subsequent years [9] - The net profit for 2025 is estimated at 1.39 billion yuan, reflecting a decrease of 29.15% from 2024 [9] - The company’s gross margin is expected to remain high, around 93.9% in 2025, indicating strong profitability [11] Market Position - The company holds a 25.4% stake in Huons BP, ensuring stable product supply and enhancing its competitive position in the market [5] - The report highlights the company as a leading player in the aesthetic medicine sector, benefiting from significant research and technological advantages [7]